Adverse effects of azacitidine: Onset, duration, and treatment
Abstract High-risk myelodysplastic syndromes present a poor prognosis, with survivals of close to only 1 year. The use of azacitidine, a DNA methyltransferase inhibitor, in this group of patients has transformed this grey image, with a demonstrated improvement in survival. Responses to survival are attained in a progressive manner, providing that the drug is used continually. This requires a good control of the adverse effects of the drug, which are primarily in the first cycles of treatment. The hematological adverse effects can be handled with transfusions and growth factors. The nonhematological adverse effects can be prevented with the use of antiemetics and a good technique of drug administration..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2011 |
---|---|
Erschienen: |
2011 |
Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
---|---|
Enthalten in: |
Advances in therapy - 28(2011), Suppl 4 vom: Juni, Seite 1-5 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Martínez-Francés, Antonio [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© Springer Healthcare 2011 |
---|
doi: |
10.1007/s12325-011-0021-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR024924458 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR024924458 | ||
003 | DE-627 | ||
005 | 20230519153652.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201007s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-011-0021-5 |2 doi | |
035 | |a (DE-627)SPR024924458 | ||
035 | |a (SPR)s12325-011-0021-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Martínez-Francés, Antonio |e verfasserin |4 aut | |
245 | 1 | 0 | |a Adverse effects of azacitidine: Onset, duration, and treatment |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer Healthcare 2011 | ||
520 | |a Abstract High-risk myelodysplastic syndromes present a poor prognosis, with survivals of close to only 1 year. The use of azacitidine, a DNA methyltransferase inhibitor, in this group of patients has transformed this grey image, with a demonstrated improvement in survival. Responses to survival are attained in a progressive manner, providing that the drug is used continually. This requires a good control of the adverse effects of the drug, which are primarily in the first cycles of treatment. The hematological adverse effects can be handled with transfusions and growth factors. The nonhematological adverse effects can be prevented with the use of antiemetics and a good technique of drug administration. | ||
650 | 4 | |a adverse effects |7 (dpeaa)DE-He213 | |
650 | 4 | |a azacitidine |7 (dpeaa)DE-He213 | |
650 | 4 | |a myelodysplastic syndromes |7 (dpeaa)DE-He213 | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 28(2011), Suppl 4 vom: Juni, Seite 1-5 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:28 |g year:2011 |g number:Suppl 4 |g month:06 |g pages:1-5 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-011-0021-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 28 |j 2011 |e Suppl 4 |c 06 |h 1-5 |